Physician profile
David Leszkowitz
NPI 1972546299
$21,141.10
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,244 · 2020: $1,289 · 2021: $1,253 · 2022: $6,791 · 2023: $4,447 · 2024: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,640 · Food and Beverage: $924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,640.00 |
| Food and Beverage | $924.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $10,660.61 | 2019-2023 | Vivitrol |
| Mdd US Operations, LLC | $5,485.44 | 2019-2020 | |
| Orexo US, INC. | $646.30 | 2019-2023 | Zubsolv |
| Indivior INC. | $543.85 | 2019-2023 | Sublocade |
| Allergan, INC. | $506.90 | 2020 | |
| Abbvie INC. | $429.39 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $356.47 | 2019-2023 | Xifaxan |
| Lilly USA, LLC | $316.93 | 2019-2021 | |
| Titan Pharmaceuticals, INC. | $305.36 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $272.85 | 2019-2023 | Austedo |
| Glaxosmithkline, LLC. | $244.27 | 2019-2023 | |
| Novo Nordisk INC | $204.61 | 2019-2021 | |
| Braeburn INC. | $152.71 | 2023-2024 | Brixadi |
| Otsuka America Pharmaceutical, INC. | $148.51 | 2020-2023 | Abilify Maintena |
| Biodelivery Sciences International, INC. | $131.93 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $116.93 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $103.35 | 2022 | |
| Ironshore Pharmaceuticals INC. | $74.59 | 2019 | |
| Novartis Pharmaceuticals Corporation | $59.40 | 2020-2022 | |
| Uswm, LLC | $49.85 | 2021-2022 | |
| Baudax Bio INC. | $48.19 | 2022 | |
| Gilead Sciences, INC. | $40.81 | 2021-2022 | |
| Redhill Biopharma INC. | $38.23 | 2021 | |
| Amarin Pharma, INC. | $35.24 | 2020-2021 | |
| Pfizer INC. | $22.49 | 2023 | |
| Pear Therapeutics (US), INC. | $21.67 | 2022 | |
| Janssen Biotech, INC. | $20.00 | 2021 | |
| Collegium Pharmaceutical, INC. | $19.41 | 2023 | Belbuca |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.07 | 2021 | |
| Orthofix Medical, INC. | $18.34 | 2019 | |
| Merck Sharp & Dohme LLC | $18.20 | 2020 | |
| Janssen Pharmaceuticals, INC | $17.56 | 2023 | Xarelto |
| Eisai INC. | $11.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Leszkowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.